Creo Medical Group, a biotech firm based in South East Wales, has floated on AIM after raising £20m from investors.
The company, which has been backed by Finance Wales, Pentax Medical and the Angel CoFund, specialises in the field of surgical endoscopy.
Founded in 2009, Creo produces an innovative device that allows physicians to operate without puncturing the patient’s skin.
We are coming to the end of November and it is pretty clear the Xmas Bells are ringing loud and clear – my local radio station is beating out the painful Xmas ‘hits’, TV Ads are in full swing and the weather has certainly got that Xmas nippy feel to it. December is normally the strongest month of the year although the ‘Santa Rally’ tends to happen right at the end and often in the gap between Xmas and New Year – but the trend is very strong and I am happy to be going into this final month of 2016 with only a small Short Position on the FTSE100 which if we get a pullback in the early days of December I would be quite happy to close out.
Share Talk talked with Justin Tooth of Ferrum Crescent about their recent raising of £550000. We discuss the historical work program in regards to the BFS with BVI/Ovation. Justin provides an update to the Toral project and the work program as was previously announced.
Share Talk spoke to European Metal Holdings about their Cinovec project. We talk about today’s RNS and how it will fit in with next years Pre Feasibility Study. We talk about the forward looking news flow towards the end of this phase of the project.
Amryt, a clinical-stage specialty pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, is pleased to announce that it has reached an agreement with Aegerion Pharmaceuticals, Inc. (“Aegerion”), the NASDAQ-listed biopharmaceutical company, for the exclusive rights to sell Aegerion’s drug, LOJUXTA (lomitapide), across the European Union (“EU”) and other territories (the “Licence Agreement”). The Licence Agreement will add to the Company’s growing portfolio of orphan products and is expected to be immediately cash generative for Amryt.
Steve Larratt, Share Research Analyst for Share Talk, talks exclusively to Joe Wiley, CEO of Amryt Pharma about last week’s transformational licence agreement announced on 5 December 2016.
Regency Mines (LON:RGM) seeks to develop a large and profitable natural resource enterprise with diverse revenue streams and significant potential for capital growth and share price appreciation.
Regency Mines plc follows a long-term corporate strategy designed to create and realize value for shareholders throughout all phases of the commodity cycle. Regency employs its financial and technical skills to identify and develop natural resource projects and investments with attractive risk weighted return profiles. These may include early stage exploration projects as well as more mature investments with near-cash flow potential.